Searched for
USFDA NEWS
Sell or Hold: Citi maintains buy on Cipla; Motilal Oswal recommends buy on RIL post AGMBrokerages remain bullish on Cipla and Reliance Industries, citing strong growth drivers and attractive valuations. Citi highlights regulat...- USFDA concludes inspection at Jubilant HollisterStier's Spokane plant with 8 observationsJubilant Pharmova announced its US subsidiary, Jubilant HollisterStier LLC, underwent a USFDA inspection. The facility in Spokane, Washingt...
- Concord Biotech shares jump 8% on USFDA nod for Mycophenolate Mofetil oral suspensionConcord Biotech shares saw a significant jump on Wednesday. This surge followed the company's announcement of receiving approval from the U...
- USFDA issues Form-483 with 5 observations to Ajanta Pharma's Paithan facilityAjanta Pharma said the US FDA has issued Form-483 with five observations after inspecting its Paithan manufacturing facility in Maharashtra...
- Stocks in news: HDFC Bank, ICICI Bank, RIL, Trent, Jio FinancialIndian markets are set for a dynamic start today. Investors will closely watch the Q4 results from banking giants HDFC Bank and ICICI Bank....
- Stocks in news: Torrent Power, GAIL, J&K Bank, Ola Electric, Vedanta, InfosysMarkets ended higher for the third consecutive session amidst volatility. Today's trade will focus on ceasefire developments and the MPC me...
- Aurobindo Pharma's Eugia Unit-3 gets warning letter from USFDA, shares fallAurobindo Pharma's subsidiary Eugia Pharma Specialities received a warning letter from the USFDA concerning its formulations manufacturing ...
- Alembic gets USFDA nod for generic skin treatment creamThe approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Desonide Cream, 0.05 per cent, of Padagis US LL...
- Can USFDA all-clear for Duvvada earn Dr Reddy’s stock a rerating?The Duvvada news has lifted a big overhang from the stock, said Edelweiss Securities.
- Is Sun Pharma's Halol site close to a rebound?About 40% of the US revenues of Sun Pharmaceutical Industries, India's most valuable pharmaceutical company, is linked to its Halol site.
- Glenmark's Ankleshwar plant gets EIR report from USFDA"The EIR is issued by the FDA only if it finds the facility to be deemed acceptable," the company said in a BSE filing.
- Divi's Laboratories hits 52-week low as Emkay raises concernsThe five observations are explained by the USFDA highlighted that no proper control was exercised over a computer system, facility equipmen...
- Don’t worry about FDA, time to buy pharmaCadila Healthcare is an example of how a supposedly severe FDA clamp could also translate into an opportunity to accumulate the stock.
- Orchid Pharma gets EIR report from USFDA on inspection closureOrchid Pharma has received Establishment Inspection Report (EIR) from the US health regulator on the successful inspection closure for its ...
- USFDA becoming dreaded word in Dalal Street; pharma companies need to keep Street in the loopThe stock of drug major Dr Reddy’s Labs (DRL) crashed 22% in the last three days, swiftly eroding the gains made over the last five months.
- USFDA glare, high valuations trigger correction in pharma stocksWhile the broad-based Nifty Pharma index is down 12.4% from November 4 till date, the loss has been more pronounced in individual stocks.
- Dabur to submit additional information for its Alwar unit to USFDAHomegrown FMCG major Dabur said the USFDA has sought "additional information" for its Alwar unit and the company is "in process of submitti...
- IPCA Laboratories stock slumps 16 per centShares of IPCA Laboratories slumped nearly 16 per cent to hit its 52-week low in early trade amid reports of stock downgrade.
- USFDA pulls up Smruthi Organics for norms violation in unitSmruthi Organics today said it has received a notification from the USFDA highlighting violations of manufacturing norms at its Solapur pla...
- Ranbaxy Laboratories: Settlement takes away gains from Lipitor launchDrug maker Ranbaxy's fortunes have reversed swiftly-with the cost of settlement with the USFDA almost wiping off the gains from the exclusi...
Load More
